A Phase 2 interventional study of Sotagliflozin (SAR439954) and Placebo in Diabetes Mellitus, sponsored by Sanofi. Completed at 1 site in Germany. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2022-04-25.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Diabetes Mellitus by Sanofi — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus · Sanofi.
Among the 33 studies in Diabetes Mellitus by Sanofi, this one is the 22nd largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 in phase 2, and was the 31st registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →None of the 33 studies in Diabetes Mellitus by Sanofi is open now. The open studies under Diabetes Mellitus, anywhere →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 188 across the 31 interventional studies, 4,589 across the 1 observational. Of the 33 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 33 studies in Diabetes Mellitus by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To compare the metabolic and gastrointestinal pharmacodynamic (PD) effects of an 8 weeks treatment with sotagliflozin once daily (QD) to an 8 weeks treatment to empagliflozin QD in mild or moderate hypertensive T2DM patients on a stable treatment regimen with metformin and an angiotensin converting enzyme (ACE) inhibitor or Angiotensin Receptor Blocker (ARB) under standardized diet conditions.
Secondary Objectives:
The total study duration per patient is 70-105 days (for patients without drug washout/switch period), and up to 175 days (for patients with drug washout/switch period), including 2-30 days of screening, 5 days of run-in period, 56 days of treatment period, and a 7-14 days of follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female patients with Type 2 Diabetes Mellitus (T2DM) (diagnosed at least 1 year before screening visit), between 18 and 74 years of age, inclusive, with:
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sotagliflozin 2 tablets administered once daily with 1 empagliflozin placebo capsule prior to the first meal of the day
Drug: Sotagliflozin (SAR439954) · Drug: Placebo
Empagliflozin 1 capsule administered once daily with 2 sotagliflozin placebo tablets prior to the first meal of the day
Drug: Placebo · Drug: Empagliflozin
Pharmaceutical form: tablet Route of administration: oral
Pharmaceutical form: tablet Route of administration: oral
Pharmaceutical form: capsule Route of administration: oral
Also known as: Jardiance®
Pharmaceutical form: capsule Route of administration: oral
Assessment of pharmacodynamic (PD) parameters in feces
Change from baseline in fecal sodium excretion
Time frame: Baseline and on Day 55 and 56 (over 48 hours)
Assessment of pharmacodynamic (PD) parameters in feces
Change from baseline in fecal short-chain fatty acids (SCFA)
Time frame: Baseline and on Day 55 and 56 (over 48 hours)
Assessment of pharmacodynamic (PD) parameters in feces
Change from baseline in fecal pH
Time frame: Baseline and on Day 55 and 56 (over 48 hours)
Assessment of PD parameters in urine
Change from baseline in 24-hour urinary glucose excretion
Time frame: Baseline and on Day 56 (over 24 hours)
Assessment of PD parameters in urine
Change from baseline in 24-hour sodium excretion
Time frame: Baseline and on Day 56 (over 24 hours)
Assessment of PD parameters in blood
14 hour plasma glucose profile after standardized meals
Time frame: Baseline and on Day 56
Assessment of PD parameters in blood
14 hour plasma glucagon-like peptide 1 (GLP-1) profile after standardized meals
Time frame: Baseline and on Day 56
Fasting metabolic laboratory panel
Change from baseline in fasting plasma glucose
Time frame: Baseline and on Day 56
Ambulatory Blood Pressure Measurement (ABPM)
Change from baseline in average 24h systolic arterial pressure
Time frame: Baseline and on days 54 until Day 56
Cardiovascular parameters
Change from baseline in plasma aldosterone
Time frame: Baseline and on Day 56
Pulse wave velocity
Change from baseline in carotid-femoral pulse wave velocity
Time frame: Baseline and on Day 55
Continuous Glucose Monitoring (CGM)
Change from baseline in average diurnal glucose
Time frame: Baseline, last 3 days of treatment
Echocardiography
Change from baseline in left ventricular ejection fraction (LVEF)
Time frame: Baseline and on Day 54
Echocardiography
Change from baseline in left ventricular end-diastolic diameter
Time frame: Baseline and on Day 54
Plasma Volume Measurement
Change from baseline in plasma volume
Time frame: Baseline and on Day 54
Adverse events
Number of patients with reported adverse events
Time frame: Over 15 weeks
Assessment of pharmacokinetic (PK) parameters: Cmax
Sotagliflozin: maximum plasma concentration observed (Cmax)
Time frame: 24 hours after last investigational medicinal product (IMP) administration
Assessment of pharmacokinetic (PK) parameters: Ctrough
Sotagliflozin: plasma concentration observed before administration during repeated dosing (Ctrough)
Time frame: 24 hours after last IMP administration
Assessment of pharmacokinetic (PK) parameters: AUCtau
Sotagliflozin: Area under the plasma concentration versus time curve calculated using the trapezoidal method over the dosing interval (AUCtau)
Time frame: 24 hours after last IMP administration
Assessment of pharmacokinetic (PK) parameters: tmax
Sotagliflozin: First time to reach Cmax (tmax)
Time frame: 24 hours after last IMP administration
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Mar 2018 to primary completion in Apr 2019, 13 months.
Of 65 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's 13 months is close to that.
Counting every sponsor, half of 147 studies reached it within 27 months; a quarter within 12 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotagliflozin